Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York. more
Time Frame | MNMD | Sector | S&P500 |
---|---|---|---|
1-Week Return | -4.32% | -0.94% | -2.6% |
1-Month Return | -6.96% | -5.08% | -1.08% |
3-Month Return | 20.61% | -10.62% | 3.45% |
6-Month Return | -4.07% | -6.18% | 8.57% |
1-Year Return | 82.95% | 1.98% | 24.3% |
3-Year Return | -72.07% | -0.93% | 25.58% |
5-Year Return | 58900% | 33.84% | 84.07% |
10-Year Return | -73.72% | 102.52% | 185.12% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 6.68K | - | 2.62M | 3.22M | 3.16M | [{"date":"2019-12-31","value":0.21,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":81.17,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":98.11,"profit":true}] |
Gross Profit | (6.68K) | - | (2.62M) | (3.22M) | (3.16M) | [{"date":"2019-12-31","value":-668369,"profit":false},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-261600000,"profit":false},{"date":"2022-12-31","value":-322300000,"profit":false},{"date":"2023-12-31","value":-316200000,"profit":false}] |
Gross Margin | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 461.50K | 33.03M | 93.85M | 66.33M | 93.87M | [{"date":"2019-12-31","value":0.49,"profit":true},{"date":"2020-12-31","value":35.19,"profit":true},{"date":"2021-12-31","value":99.99,"profit":true},{"date":"2022-12-31","value":70.67,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (468.18K) | (33.03M) | (96.36M) | (66.33M) | (93.87M) | [{"date":"2019-12-31","value":-46818000,"profit":false},{"date":"2020-12-31","value":-3303000000,"profit":false},{"date":"2021-12-31","value":-9636400000,"profit":false},{"date":"2022-12-31","value":-6633100000,"profit":false},{"date":"2023-12-31","value":-9386600000,"profit":false}] |
Total Non-Operating Income/Expense | - | (1.07M) | (698.00K) | 11.03M | 2.94M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-9.71,"profit":false},{"date":"2021-12-31","value":-6.33,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":26.7,"profit":true}] |
Pre-Tax Income | (1.12M) | (33.94M) | (94.19M) | (56.80M) | (95.73M) | [{"date":"2019-12-31","value":-111580600,"profit":false},{"date":"2020-12-31","value":-3393700000,"profit":false},{"date":"2021-12-31","value":-9419300000,"profit":false},{"date":"2022-12-31","value":-5679600000,"profit":false},{"date":"2023-12-31","value":-9573200000,"profit":false}] |
Income Taxes | (3.69) | 164.00K | (1.16M) | (9.54M) | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-705.49,"profit":false},{"date":"2022-12-31","value":-5814.02,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | - | (34.10M) | (93.04M) | (47.26M) | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-3410100000,"profit":false},{"date":"2021-12-31","value":-9303600000,"profit":false},{"date":"2022-12-31","value":-4726100000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | - | (33.94M) | (93.04M) | (56.80M) | (76.77M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-3393700000,"profit":false},{"date":"2021-12-31","value":-9303600000,"profit":false},{"date":"2022-12-31","value":-5679600000,"profit":false},{"date":"2023-12-31","value":-7677100000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (1.12M) | (34.10M) | (93.04M) | (47.26M) | (95.73M) | [{"date":"2019-12-31","value":-111580600,"profit":false},{"date":"2020-12-31","value":-3410100000,"profit":false},{"date":"2021-12-31","value":-9303600000,"profit":false},{"date":"2022-12-31","value":-4726100000,"profit":false},{"date":"2023-12-31","value":-9573200000,"profit":false}] |
EPS (Diluted) | - | (2.69) | (3.04) | (1.92) | (2.32) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-269.01,"profit":false},{"date":"2021-12-31","value":-304,"profit":false},{"date":"2022-12-31","value":-192,"profit":false},{"date":"2023-12-31","value":-232,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
MNMD | |
---|---|
Cash Ratio | 8.88 |
Current Ratio | 9.00 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
MNMD | |
---|---|
ROA (LTM) | -25.38% |
ROE (LTM) | -54.61% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
MNMD | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.18 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.82 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
MNMD | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 2.00 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Mind Medicine Inc (MNMD) share price today is $7.08
Yes, Indians can buy shares of Mind Medicine Inc (MNMD) on Vested. To buy Mind Medicine Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MNMD stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Mind Medicine Inc (MNMD) via the Vested app. You can start investing in Mind Medicine Inc (MNMD) with a minimum investment of $1.
You can invest in shares of Mind Medicine Inc (MNMD) via Vested in three simple steps:
The 52-week high price of Mind Medicine Inc (MNMD) is $12.22. The 52-week low price of Mind Medicine Inc (MNMD) is $3.49.
The price-to-earnings (P/E) ratio of Mind Medicine Inc (MNMD) is
The price-to-book (P/B) ratio of Mind Medicine Inc (MNMD) is 2.00
The dividend yield of Mind Medicine Inc (MNMD) is 0.00%
The market capitalization of Mind Medicine Inc (MNMD) is $525.05M
The stock symbol (or ticker) of Mind Medicine Inc is MNMD